phenylpropionate

6065

For intravenous injection as a solvent for injection using water (0.5-1 g diluted in 4 ml of the solvent, 2 g – 10 ml); for intravenous infusion is used as a solvent of 0.9% sodium chloride solution or 5% dextrose solution (2.1 g diluted in 50-100 ml of solvent). Infusion Duration – 50-60 minutes. For intramuscular injection phenylpropionate using water or 1% lidocaine (for a dose of 0.5 g – 2 mL for dose of 1 g – 4 mL).

Side effects: Allergic reactions: urticaria, chills or fever, rash, pruritus, rarely -bronhospazm, eosinophilia, malignant exudative erythema (Stevens-Johnson syndrome), toxic epidermal necrolysis (Lyell’s syndrome), angioneurotic edema, rare – anaphylactic shock. On the side nervous system: headache, dizziness. From the mochevydelitelnoy system: renal dysfunction, oliguria, interstitial nephritis. From the digestive system: nausea, vomiting, diarrhea or constipation, bloating, abdominal pain, goiter, liver dysfunction, rarely – stomatitis , glossitis, pseudomembranous enterocolitis. From the side of hematopoiesis: . hemolytic anemia, leukopenia, neutropenia, granulocytopenia, thrombocytopenia, anticoagulation since the cardiovascular system: a potentially life-threatening arrhythmias after a rapid bolus into the central vein. Local reactions: phlebitis, pain along veins, pain and infiltration at the site of intramuscular injection. Laboratory findings: azotemia, increased concentration of urea in the blood, increased activity of “liver” transaminases and alkaline phosphatase, hypercreatininemia, hyperbilirubinemia, a positive Coombs’ test. Other: superinfection (including candidiasis phenylpropionate vaginitis).

 

Overdose symptoms: seizures, encephalopathy (in the case of high doses, especially in patients with renal insufficiency), tremors, neuromuscular excitability. Treatment: symptomatic, there is no specific antidote.

Interaction with other drugs
increases the risk of bleeding when combined with antiplatelet agents, non-steroidal anti-inflammatory drugs.
Renal disease probability is increased by simultaneous reception with aminoglycosides, polymyxin B, and “loop” diuretics.
Drugs that block tubular secretion, increase the plasma concentrations of cefotaxime and slow down its excretion .
Pharmaceutical incompatible with solutions of other antibiotics in the same syringe or dropper.

Cautions
In the first weeks of treatment may be phenylpropionate pseudomembranous colitis manifested by severe prolonged diarrhea. In this case stop taking the drug and prescribe appropriate therapy, including vancomycin or metronidazole.
Patients who had a history of allergic reaction to penicillin, may be sensitive to cephalosporin antibiotics.
In the treatment of drug over 10 days is necessary to monitor the number of blood cells.
During treatment with cefotaxime you may receive false-positive and false-positive Coombs reaction urine glucose.
If concomitant use of cefotaxime and ethanol development disulfiramopodobnyh reactions (facial flushing, abdominal cramps and in the stomach, nausea, vomiting, headache, decreased blood pressure, tachycardia, shortness of breath).

Product form
Powder for solution for intravenous and intramuscular administration of 0.5 g,
1 g, 2 g colorless vials or dark glass capacity of 10 ml or 20 ml.
1, 5 or 10 units with instructions for use placed in a pile of cardboard.
50 vials are placed in a box made of cardboard with instructions for use 5 for delivery in hospitals.
1 vial, 1 vial with solvent (10 ml sodium chloride for injection 0.9%) were placed in blisters. 1 contour cell package with lancet ampulnam and instructions for use of the drug is placed in a pile of cardboard.
5 vials of the drug placed in blisters. 1 contour cell package with the drug, 1 contour cell package with 5 solvent ampoules (10 ml sodium chloride for injection 0.9%), scarifier ampoule instructions for use of the drug is placed in a pile of cardboard. When using phenylpropionate ampoules with a ring or a break-point and notched scarifier ampoule do not invest.